Abstract:Abstract There are growing numbers of individuals with psoriasis who have clear or nearly clear skin (i.e. disease control) on high-cost biologic drugs. They currently continue biologic treatment indefinitely, resulting in a long-term drug and healthcare burden. Prior research indicates that some sustain disease control on less frequent doses than the current ‘one-size-fits-all’ standard dosing regimen, particularly those with higher serum drug concentrations. This indicates a role for therapeutic drug monitoring (TDM) in enabling personalized drug minimization strategies. We sought to develop a TDM dashboard, incorporating a pharmacokinetic (PK) model to deliver real-time predictions for informing personalized dosing decisions. We searched the PKPDAI and PubMed databases for models describing population pharmacokinetics of the exemplar psoriasis biologic risankizumab. The PK model was run using the MAPBAYR R package, incorporating serum drug concentrations as Bayesian priors. The model was validated using an independent real-world psoriasis dataset (n = 30, BSTOP study) by calculating the mean prediction error (MPE) and root-mean-square error (RMSE). Finally, the model was incorporated into a bespoke TDM dashboard, developed using open-source R Shiny software. We identified a two-compartment PK model with first-order absorption and elimination processes derived from pooled phase I–III risankizumab clinical trial data (13 123 observations from 1899 patients, 71% male, median age 47 years, median bodyweight 87 kg). The PK model was developed using a nonlinear mixed-effects modelling approach and accounted for interindividual variability in drug clearance, volume of distribution, absorption constant and bioavailability. Covariates incorporated into the model included bodyweight and serum concentrations of anti-risankizumab antibody, albumin, creatinine, and high-sensitivity C-reactive protein. We validated the model using the independent real-world psoriasis dataset (MPE 0.74 mg L−1, RMSE 2.77 mg L−1) and incorporated it into a bespoke TDM dashboard (i.e. a real-time dosing interval calculator). The TDM dashboard is a user-friendly online interface that generates personalized dose interval recommendations following input of relevant variables (date of last dose, serum drug concentration, covariates and Psoriasis Area and Severity Index score) and a graphic of the PK profile. A randomized controlled feasibility trial (launch Q2 2024) will determine the patient and clinician acceptability and real-world practicality of TDM dashboard-informed biologics dosing. The dashboard enables proactive TDM, so that drug exposure can be minimized in individuals with psoriasis who have clear or nearly skin for ≥ 12 months on risankizumab. A pharmacodynamic turnover model is being developed to link to the PK model, with the potential to include other biologic drugs for optimal impact on overall drug exposure, healthcare burden and cost.

Therapeutic Drug Monitoring to Optimize Risperidone Treatment in Children with Autism Spectrum Disorder

Efficacy and Safety of Long-Acting Risperidone on Early Onset Schizophrenia in Adolescent Patients

Weight Gain and Metabolic Consequences of Risperidone in Young Children with Autism Spectrum Disorder

The effect of therapeutic drug monitoring of risperidone and aripiprazole on weight gain in children and adolescents: the SPACe 2: STAR (trial) protocol of an international multicentre randomised controlled trial

Assessing the Clinical Efficacy of Therapeutic Drug Monitoring for Risperidone and Paliperidone in Patients with Schizophrenia: Insights from a Clinical Data Warehouse

A Machine Learning Model to Predict Risperidone Active Moiety Concentration Based on Initial Therapeutic Drug Monitoring

Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials.

Metabolic Side Effects of Risperidone in Pediatric Patients with Neurological Disorders: A Prospective Cohort Study

Therapeutic drug monitoring in children and adolescents with schizophrenia-spectrum, affective, behavioural, tic and other psychiatric disorders treated with aripiprazole: results of the TDM-VIGIL pharmacovigilance study

Factors influencing concentrations of risperidone and 9-hydroxyrisperidone in psychiatric outpatients taking immediate-release formulations of risperidone

Risperidone and the 5‐HT2A Receptor Antagonist M100907 Improve Probabilistic Reversal Learning in BTBR T + Tf/j Mice

Risperidone and aripiprazole for autism spectrum disorder in children: an overview of systematic reviews

Long-Term Effectiveness of Off-Label Risperidone Treatment in Children and Adolescents: A Randomized, Placebo-Controlled Discontinuation Study

Current Status of Therapeutic Drug Monitoring in Mental Health Treatment: A Review

Core Signs and Symptoms in Children with Autism Spectrum Disorder Improved after Starting Risperidone and Aripiprazole in Combination with Standard Supportive Therapies: A Large, Single-Center, Retrospective Case Series

Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM

Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes

Pharmacogenetic intervention in the Child and Adolescent Autism Day Therapeutic Unit

Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial

BT34 Minimizing drug exposure in psoriasis using a therapeutic drug monitoring dashboard

Observation on Clinical Efficacy of Risperidone in Treatment of Children and Adolescents with Schizophrenia